---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Effect on quality measures"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Effect on quality measures. Topics: MIPS Quality ID 410: description, measure type, and denominator; MIPS Quality ID 410: numerator benchmarks for PGA, BSA, PASI, and DLQI; MIPS Quality ID 410: six-month treatment period and denominator exception; MIPS Quality ID 410: reference list of systemic medications, oral agents; 5 further topics. 9 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Envudeucitinib on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### MIPS Quality ID 410: description, measure type, and denominator

> “Percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician-or patient- reported disease activity levels.”
> “All patients with a diagnosis of psoriasis vulgaris and treated with a systemic medication.”
> “For this measure, the patient must ONLY be diagnosed with psoriasis vulgaris (L40.0) and no other concurrent psoriasis diagnosis.”
> “Therefore, patients meet criteria when they have been diagnosed with psoriasis vulgaris AND are on a systemic medication PRESCRIBED BY THE PROVIDER BEING EVALUATED FOR THE MEASURE.”
> “For the purposes of MIPS implementation, this patient-intermediate measure is submitted a minimum of once per patient during the performance period.”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

| Field | Specification text |
| --- | --- |
| Measure type | “Intermediate Outcome – High Priority” |
| Telehealth | “TELEHEALTH ELIGIBLE: This measure is appropriate for and applicable to the telehealth setting.” |

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

### MIPS Quality ID 410: numerator benchmarks for PGA, BSA, PASI, and DLQI

> “Patients who have a documented physician global assessment (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI) that meet any one of the below specified benchmarks.”
> “To satisfy this measure, a patient must achieve any ONE of the following:”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

| Instrument | Numerator benchmark |
| --- | --- |
| PGA | “PGA (5-point OR 6-point scale) ≤ 2 (clear to mild skin disease)” |
| BSA | “BSA < 3% (mild disease)” |
| PASI | “PASI < 3 (no or minimal disease)” |
| DLQI | “DLQI ≤ 5 (no effect or small effect on patient’s quality of life)” |

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-3"></a>

### MIPS Quality ID 410: six-month treatment period and denominator exception

> “Consecutive Months – The consecutive treatment allows gaps in the medication treatment up to a total of 4 weeks during the 6 month period.”
> “Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI (G9765)”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-4"></a>

### MIPS Quality ID 410: reference list of systemic medications, oral agents

> “Denominator Criteria for Systemic Medication [G9764] may be defined by the following examples, however, other medications that meet the intent of this component may also be used:”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

| Brand name | Chemical name | Mechanism of action or type of systemic | Indication |
| --- | --- | --- | --- |
| Sotyktu | “deucravacitinib” | “Inhibits tyrosine kinase 2 (TYK2)” | “Psoriasis” |
| Otezla | “apremilast” | “Blocks phosphodiesterase-4” | “Psoriasis, Psoriatic arthritis” |
| Neoral | “cyclosporine, modified” | “Blocks lymphocytes (T cells) and lymphokines” | “Psoriasis” |
| Jylamvo | “methotrexate” | “Inhibits dihydrofolic acid reductase” | “Psoriasis” |
| Soriatane | “acitretin” | “Unknown; activates retinoid receptors” | “Psoriasis” |

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-5"></a>

### MIPS Quality ID 410: rationale and clinical recommendation statements on treatment goals

> “A significant proportion of psoriasis patients who are receiving treatment remain unsatisfied with their therapies due to various reasons including lack of or loss of efficacy, side effects, and inconvenience, among others.”
> “Treatment dissatisfaction also contributes to patients discontinuing their medication.”
> “Treatment goals (assessment after 10 to 16 weeks, and every 8 weeks thereafter): PASI 75 or PGA of ‘clear’ or ‘almost clear’; or DLQI of 0 or 1 (Pathirana, 2009).”
> “Minimum efficiency (‘lowest hurdle’): PASI 50; DLQI<5 or improvement by at least 5 points (Pathirana, 2009).”
> “Treatment ‘success’ defined as PASI 75 response (or PASI 50 response and DLQI≤5) (Baker, 2013).”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-6"></a>

### MIPS Quality ID 485: description, measure type, denominator, and numerator for itch severity

> “The percentage of patients aged 8 years and older, with a diagnosis of psoriasis where at an initial (index) visit have a patient-reported itch severity assessment performed, score greater than or equal to 4, and who achieve a score reduction of 3 or more points at a follow-up visit.”
> “Patients who achieve an assessment score that is reduced by 3 or more points (minimal clinically important difference) from the initial (index) assessment score.”
> “To successfully report this measure, the physician(s) and/or provider(s) of the same clinical practice must use the same assessment tool for both the initial (index) AND follow-up assessments using one of the validated tools (NRS, VRS, or ItchyQuant).”
> “For the purposes of MIPS implementation, this visit measure is submitted each time a patient has a denominator eligible encounter during the performance period.”

Source: [CMS MIPS Quality ID 485 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_485_MIPSCQM.pdf)

| Field | Specification text |
| --- | --- |
| Measure type | “Patient-Reported Outcome-based Performance Measure – High Priority” |
| Age | “Patients aged ≥ 8 years on the date of the encounter” |
| Diagnosis codes | “Diagnosis of psoriasis on the date of the encounter (ICD-10-CM): L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9” |
| Encounters | “At least two patient encounters during the performance period” |
| Index itch score | “Initial (index visit) Numeric Rating Scale (NRS), Visual Rating Scale (VRS), or ItchyQuant assessment score of greater than or equal to 4” |

Source: [CMS MIPS Quality ID 485 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_485_MIPSCQM.pdf)

<a id="topic-2.1.2.13-7"></a>

### MIPS Quality ID 485: rationale on pruritus in psoriasis

> “Psoriasis is a chronic inflammatory disease in which pruritus is a frequent symptom.”
> “Chronic inflammatory skin diseases, such as psoriasis, are pruritic and tremendously burdensome; with more than 70 percent of psoriasis patients suffering from itch (Reich,2016).”
> “Recommendation: Pruritus is a significant symptom of psoriasis. An itch severity assessment is recommended to appropriately assess the degree of pruritus when present.”

Source: [CMS MIPS Quality ID 485 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_485_MIPSCQM.pdf)

<a id="topic-2.1.2.13-8"></a>

### QCDR measure AAD15: appropriate assessment and treatment of severe psoriasis

| Field | Specification text |
| --- | --- |
| Measure description | “Percentage of patients with a diagnosis of psoriasis with a documented Body Surface Area (BSA) greater than 10% for whom phototherapy or an oral systemic or biologic medication was prescribed.” |
| Denominator | “All patients regardless of age with a diagnosis of psoriasis.” |
| Numerator | “Performance Met: Patient with a documented BSA greater than 10% is prescribed phototherapy or an oral systemic or biologic medication.” |
| Denominator exceptions | “Patient declines treatment with phototherapy or an oral systemic or biologic medication; patient has contraindication(s) to therapy” |

Source: [CMS 2026 QCDR measure specifications (2026)](https://qpp-cm-prod-content.s3.amazonaws.com/uploads/3573/2026_QCDR_Measure_Specifications.xlsx)

<a id="topic-2.1.2.13-9"></a>

### QCDR measure AAD8: patient-reported quality of life in chronic skin conditions including psoriasis

| Field | Specification text |
| --- | --- |
| Measure title | “Chronic Skin Conditions: Patient Reported Quality-of-Life” |
| Measure description | “The percentage of patients aged 18 years and older with a chronic skin condition whose self-assessed quality-of-life was recorded at least once in the medical record within the measurement period.” |
| Numerator | “Patients who have a patient-reported quality-of-life assessment completed AND recorded in the medical record with a care plan* at least once within the 12-month measurement period.” |
| Conditions included | “Common conditions such as psoriasis, dermatitis, acne, rosacea, and urticaria are included because of the impact they have on patient's health and well-being.” |

Source: [CMS 2026 QCDR measure specifications (2026)](https://qpp-cm-prod-content.s3.amazonaws.com/uploads/3573/2026_QCDR_Measure_Specifications.xlsx)

<a id="topic-2.1.2.13-10"></a>

### HEDIS and NCQA measures for psoriasis

No evidence found.

<a id="topic-2.1.2.13-11"></a>

### Product-specific effect of envudeucitinib on quality measure performance

No evidence found.

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
